Cite
HARVARD Citation
Coleman, M. et al. (2021). Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leukemia & lymphoma. 62 (2), pp. 368-376. [Online].